UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Not sure what you can access? Learn more about account types.

Introduction

Several changes in microbes of the gut and decreased diversity especially in inflammatory bowel disease (IBD) are well-known. The exact pathophysiological connection is lacking, but the systemic inflammation due to the microbial alterations are assumed.

Aims & Methods

This study aimed to perform analysis of faecal microbiota composition simultaneously with body composition and lipid characteristics in Crohn’s disease (CD) patients to find specific microbiota profiles connected to altered metabolism and obesity. In our prospective cohort study, CD patients were enrolled. At the inclusion, demographic and clinical data, blood, and faecal samples were obtained. Disease activity was assessed by CDAI, and SES-CD. Laboratory tests were made including C-reactive protein (CRP), albumin and lipids (triglyceride, cholesterol). Faecal bacterial composition was assessed using shotgun method. Each patient underwent a body composition analysis via bioelectrical impedance analysis. A nutritional questionnaire was filled by each subject.

Results

We analysed 27 CD patients in this study (median age was 35 IQR 13.5 years). A 44,4% and 27,3% of patients were obese based on BMI and VFA. Beta diversities were higher in non-obese patients (VTA, p<0,001), however relative abundances did not differ. Firmicutes has a lower, while C.innocuum has a higher abundance at high cholesterol level (p=0,001, p=0,0034). Adlercreutzia, B.longum and Blautia alterations were correlated with triglyceride level. Higher Clostridia (p=0,009) and B.schinkii (p=0,032) and lower Lactobacillus (p=0,035) were connected to high VFA. B.bifidum had richness amongst low-weight patients (p=0,01). Beside Clostridia, Eubacteriales and R.hominis also correlated with waist-hip ratio (p=0,04, p=0,04 and p=0.048). Higher body fat mass was paired with increased B.schinkii (p=0,021) and decreased L.paragasseri (p=0,015) and R.intestinalis (p=0,035). Disease activity was coupled with dysbiotic elements. Microbiota alterations were found during different treatments.

Table 1. Baseline demographic and clinical characteristics of the study population [n = 27]

	n = 27
Gender (male, N, %)	9 (33.3)
Age (years, median (IQR)	35 (13.5)
Disease duration (years, median (IQR)	7 (11.0)
CDAI at inclusion, mean (± SD)	141 (97.2)
SES-CD at inclusion, mean (± SD)	7.4 (8.0)
Fecal calprotectin (ug/g, median, (IQR))	728.6 (626.3)
CRP at inclusion, mean (± SD)	17.0 (35.3)
Serum cholesterol (mmol/l, mean, ± SD)	4.3 (0.9)
Serum triglyceride (mmol/l, mean, ± SD)	1.6 (1.0)

Conclusion

Changes in Blautia, Lactobacillus, Clostridia and Bifidobacterium abundances in obesity highlight the importance of gut microbiota in diseases with similar inflammatory background. It suggests to treat obesity to achive better disease contol in IBD and it helps to develop new therapeutic approaches, such as pre- or probiotics or personalized faecal microbiota transplantation.

SHOTGUN ANALYSIS OF GUT MICROBIOTA WITH BODY COMPOSITION AND LIPID CHARACTERISTICS IN CROHN'S DISEASE

Péter Bacsur 1, Tamás Resál 1, Bernadett Farkas 1, Boldizsár Jójárt 2, Zoltán Gyuris 3, Gábor Jaksa 3, Lajos Pintér 3, Bertalan Takács 4, Sára Pál 4, Attila Gácser 4, Kata Szántó 1, Mariann Rutka 1, Renáta Bor 1, Anna Fabian 1, Klaudia Farkas 1, József Maléth 2, Zoltán Szepes 1, Tamás Molnár 1, Anita Balint 1

1 University of Szeged, Albert Szent-Györgyi Medical School, Szeged, Hungary

2 Hungarian Academy of Science University of Szeged, Szeged, Hungary

3 Delta Bio 2000 Ltd., Szeged, Hungary

4 Hungarian Centre of Excellence of Molecular Medicine University of Szeged, Szeged, Hungary

Conference

UEG Week Copenhagen 2023

Topics

IBD

Submission format

Abstract

Session

PP 05 IBD (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Why doesn’t your colleague know what an endoscopy nurse does?

YAIZA DEL CARMEN TORRES ZAMORA 1

1 Hospital universitario insular de Gran Canaria, None, Spain

Event

UEG Week Vienna 2024

Topics

Nurses

Session

Education: Creative tools

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

BAYESIAN PRIOR ELICITATION ON THE EFFICACY OF SEVEN MEDICAL THERAPIES FOR FISTULATING PERIANAL CROHN’S DISEASE

Not sure what you can access? Learn more about account types.

Introduction

Fistulating peri-anal Crohn’s disease can affect approximately 20% of patients and have a major impact on quality of life. Despite being an important area of unmet clinical need, there is a paucity of evidence for most medical treatments and a lack of dedicated clinical trials for perianal Crohn’s disease. Current studies also report a high level of heterogeneity for outcomes with both treatments and placebo - making interpretation of the available data challenging for both clinical practice and design of clinical trials. Use of Bayesian methodology offers an attractive solution to help address some of these challenges. We sought to conduct a Bayesian prior elicitation exercise to determine the efficacy of licensed medical therapies for fistulating perianal Crohn’s disease.

Aims & Methods

A formal Bayesian prior elicitation meeting was convened. This was composed of a group of 11 gastroenterologists and 5 statisticians. Consensus priors were developed leveraging both published data and expertise of the gastroenterologists, to determine one-year fistula remission rates for seven options of licensed medical treatments based on five different mechanisms of action (anti-TNF, anti-integrin, anti-IL12/23, anti-IL-23, and JAK inhibitor). Consensus priors on the efficacy of each of seven treatment options was determined relative to an elicited consensus prior for placebo control. The log-odds ratio for efficacy for each of the seven therapy options versus placebo control was also established.

Results

Consensus priors were obtained for seven medical treatments for likelihood of fistula remission at one year. The prior mean, together with a 90% prior credible interval, of the one-year fistula remission rate was 0.22 (0.05, 0.46) for placebo, 0.58 (0.09, 0.96) for intravenous infliximab, 0.39 (0.06, 0.82) for adalimumab, 0.53 (0.09, 0.93) for subcutaneous infliximab, 0.24 (0.03, 0.60) for intravenous vedolizumab, 0.44 (0.05, 0.90) for upadacitinib, 0.34 (0.04, 0.77) for ustekinumab, and 0.36 (0.04, 0.82) for risankizumab. When assessing treatment effect on the log-odds ratio scale, oral upadacitinib and subcutaneous infliximab had the strongest “priors”, with the highest probability for likely efficacy, alongside intravenous infliximab.

Conclusion

We have conducted, to the best of our knowledge, the first formal Bayesian prior elicitation exercise for efficacy of medical therapies in perianal Crohn’s disease. These priors developed for the efficacy of licensed medical therapies can be internationally validated and potentially taken forward for planning of dedicated clinical trials. Importantly, these results could be used to enhance the design and analysis of clinical trials for fistulating perianal Crohn’s disease. Notable potential benefits from these findings include: improved estimation of treatment efficacy, reduction in the required sample sizes, and with minimisation or even avoidance of placebo control arms for future dedicated fistulating perianal Crohn’s disease clinical trials.

Disclosure

NMN declares educational/travel grants and/or speaker fees from AbbVie, Bristol Myers Squibb, Celltrion, Dr Falk Pharma, Ferring, Galapagos, J&J, Lilly, Pfizer, Pharmacosmos, Takeda and Tillotts Pharma AG. RC reports personal fees from AbbVie, Galapagos, Lilly outside the submitted work, and grants from Celltrion, Ferring, Tillotts Pharma outside the submitted work; and fees from advisory board membership of AbbVie, Bristol Myers Squibb outside the submitted work. SD reports personal fees from AbbVie, Ferring, Janssen, Takeda outside the submitted work; and grants from AbbVie, Dr Falk, Janssen, outside the submitted work; and fees from advisory board membership of AbbVie outside the submitted work. HG has received speaker fees from: Janssen, Ferring, Takeda, and AbbVie, and consultancy fees from. AbbVie, Galapagos. KBK reports serving as a speaker, a consultant, and/or an advisory board member for Abbvie, Falk, Galapagos, Janssen, and Takeda. JOL reports personal fees from AbbVie, Atlantic Healthcare, Bristol Meyer Squibb, Celgene, Celltrion, Engytix, Eli Lilly, Ferring, Galapagos, Gilead, GSK, Janssen, MSD, Norgine, Pfizer, Shire, and Takeda outside the submitted work; and grants from AbbVie, Ferring, Gilead, Takeda, and Shire outside the submitted work. GWM declares consultancy fees/grant funding from AbbVie, AstraZeneca and Janssen; all outside the submitted work. KVP reports personal fees from AbbVie, DrFalk, Galapagos, Janssen, PredictImmune, Pfizer, Takeda outside the submitted work; and grants from AbbVie, Celltrion, Dr Falk, Ferring, Janssen, Takeda, Tillotts Pharma outside the submitted work; and fees from advisory board membership of AbbVie, Galapagos, Janssen, Pfizer outside the submitted work. SS reports consulting fees from Takeda, AbbVie, Merck, Ferring, Pharmacosmos, Warner Chilcott, J&J Innovative Medicine, Dr Falk Pharma, Biohit, TriGenix, Celgene, and Tillots Pharma outside the submitted work; payment or honoraria from AbbVie, Takeda, Celltrion, Pfizer, Biogen, AbbVie, J&J Innovative Medicine, Merck, Warner Chilcott, Dr Falk Pharma, outside the submitted work; and is co-director of research for the South Asian IBD Alliance. TR has received research/educational grants and/or speaker/consultation fees from Abbvie, Arena, Aslan, AstraZeneca, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, MonteRosa, Mylan, MSD, Novartis, Numab, Pfizer, Roche, Sandoz, Takeda, UCB, and XAP Therapeutics. SS reports person fees from Abbvie, Celltrion, Dr. Falk, Ipsen, Janssen, Takeda outside the submitted work. ALH has received consultancy fees from AbbVie, Bristol Myers Squibb, Celltrion, Galapagos, Johnson & Johnson, Takeda, Pfizer, and Lilly; has received honoraria from AbbVie, Bristol Myers Squibb, Celltrion, Galapogos, Johnson & Johnson, Takeda, Pfizer, Lilly; and has received support for attending meetings or travel from AbbVie, Bristol Myers Squibb, Celltrion, Galapagos, Johnson & Johnson, Takeda, Pfizer, and Lilly; all outside of the submitted work. MP reports personal fees from Janssen and Takeda outside the submitted work; and grants from AstraZeneca, Galapagos, Gilead, Pfizer outside the submitted work. All other authors declare no conflicts of interest.

BAYESIAN PRIOR ELICITATION ON THE EFFICACY OF SEVEN MEDICAL THERAPIES FOR FISTULATING PERIANAL CROHN’S DISEASE

Nurulamin Noor 1, Haiyan Zheng 2, Zhi Cao 3, Gianmarco Caruso 3, Corey Voller 2, Rachel Cooney 4, Shahida Din 5, Hannah Gordon 6, Bel Klaartje Kok 7, James O. Lindsay 8, Gordon Moran 9, Kamal Vijaykant Patel 10, Shaji Sebastian 11, Tim Raine 12, Sreedhar Subramanian 12, Ailsa L Hart 13, David Robertson 3, Miles Parkes 12

1 Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

2 University of Bath, Bath, United Kingdom

3 MRC Biostatistics Unit, Cambridge, United Kingdom

4 University Hospital Birmingham, Birmingham, United Kingdom

5 Western General Hospital, Edinburgh, United Kingdom

6 Translational Gastroenterology Unit, Oxford, United Kingdom

7 Barts Health, Royal London Hospital, London, United Kingdom

8 Digestive Disorders Clinical Academic Unit, BARTS & THE LONDON SCHOOL OF MEDICINE, London, United Kingdom

9 Nottingham Digestive Diseases Centre, Nottingham, United Kingdom

10 St George's Hopsital, London, United Kingdom

11 Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom

12 Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom

13 St Mark's Hospital, London, United Kingdom

Event

UEG Week Berlin 2025

Topics

IBD

Submission format

Abstract

Session

Treatment of fistulas in Crohn's disease

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Environmental impact of dignity shorts in bowel cancer screening

Esther Killan 1

1 NORTHUMBRIA HEALTHCARE TRUST, New Castle, United Kingdom

Event

UEG Week Vienna 2024

Topics

Nurses

Session

Abstracts II: Patient care and endoscopic techniques

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Leadership training: Optimising team management

Jeanin van Hooft 1

1 Leiden University Medical Center, Leiden, Netherlands

Event

UEG Week Vienna 2024

Topics

Nurses

Session

Management: Increase staff wellbeing

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION

Not sure what you can access? Learn more about account types.

Introduction

The GALAXI-1 study (NCT03466411) is a phase 2b study that evaluated guselkumab (GUS), a selective interleukin-23 p19 subunit antagonist, in patients with moderate-to-severe Crohn’s disease (CD).

Aims & Methods

We assessed clinical, endoscopic, and safety outcomes through 3 years in patients receiving maintenance therapy with GUS in the GALAXI-1long-term extension (LTE) study. Upon completing the treat-through Week 48 phase 2 study, patients continued in the LTE receiving 1 of 3 maintenance regimens that were assigned at randomization: GUS 100 mg subcutaneous (SC) every 8 weeks (q8w), GUS 200 mg SC every 4 weeks (q4w), or ustekinumab (UST) 90 mg SC q8w. Key efficacy endpoints assessed at Week 144 included CD Activity Index (CDAI) clinical remission, patient-reported outcome (PRO)-2 remission, and endoscopic response. Efficacy analysis sets are defined in Table 1. Safety analyses included all treated patients. The study was not powered to evaluate efficacy differences between individual GUS doses or GUS vs UST.

Results

Overall, the average duration of follow-up from baseline through Week 152 was 100.9 weeks in the combined GUS group (n=220) and 102.7 weeks in the UST group (n=114); 151 patients randomized to GUS and 48 patients randomized to UST were treated in the LTE. Study drug discontinuations in the combined GUS group from Week 48 through Week 152 were due to adverse events (AE, n[%]: 6[4]), lack of efficacy (2[1.3]), surgery 1[0.7]), lost to follow-up (4[2.6]), protocol deviation (1[0.7]), pregnancy (1[0.7]), refusal (1[0.7]), and patient withdrawal (9[6]); in the UST randomized group, due to AE (1[2.1]), patient withdrawal (3[6.3]), and other (1[2.1]). Among all randomized patients in the combined GUS group (including those who did not enter the LTE; primary efficacy analysis set), 54.1% were in clinical remission, 51.4% were in PRO-2 remission, and 34.7% were in endoscopic response at Week 144 (Table 1). Percentages of patients who achieved these outcomes at Week 144 among those who entered the LTE (LTE efficacy analysis set) and among those with available data at each visit (observed case analysis set) in the combined GUS group and UST reference arm are summarized in Table 1. In the combined GUS group, serious adverse events (SAEs, n[%]: 35[15.9]) and serious infections (12[5.5]) were infrequent. Most infections were not serious, mild to moderate in severity, and most resolved without drug withdrawal. No cases of active tuberculosis, opportunistic infections, anaphylactic/serum sickness reactions, major adverse cardiovascular event, or death occurred during the LTE.

Table 1. Clinical efficacy and endoscopic outcomes at Week 144
Endpoint	Analysis	Combined Guselkumab^a	Ustekinumab^b
Clinical remission (CDAI<150), % (n/N)	Primary efficacy analysis set (NRI)^c LTE efficacy analysis set (NRI)^d Observed case analysis set^e	54.1 (100/185) 68.2 (103/151) 95.4 (103/108)	46.0 (29/63) 64.6 (31/48) 83.8 (31/37)
PRO-2 remission (AP mean daily score ≤1 and SF mean daily score ≤3, and no worsening of AP or SF from baseline), n/N (%)	Primary efficacy analysis set (NRI)^c LTE efficacy analysis set (NRI)^d Observed case analysis set^e	51.4 (95/185) 64.2 (97/151) 89.8 (97/108)	39.7 (25/63) 58.3 (28/48) 75.7 (28/37)
Endoscopic response (≥50% improvement from baseline in SES-CD or SES-CD≤2), n/N (%)	Primary efficacy analysis set (NRI)^c LTE efficacy analysis set (NRI)^d Observed case analysis set^e	34.7 (61/176) 43.0 (61/142) 73.5 (61/83)	19.4 (12/62) 25.5 (12/47) 41.4 (12/29)
AP, abdominal pain; CDAI, Crohn's Disease Activity Index; LTE, long-term extension; NRI, nonresponder imputation; PRO-2, patient reported outcome components of the CDAI [abdominal pain and stool frequency]; SES-CD, Simple Endoscopic Score for Crohn’s Disease; SF, stool frequency ^aIncludes patients randomized to the following guselkumab induction/maintenance regimens: 200 mg IV →100 mg SC q8w; 600 mg IV →200 mg SC q4w; 1200 mg IV →200 mg SC q4w ^bPatients randomized to ustekinumab ^cPrimary efficacy analysis set consists of randomized patients who received ≥1 dose of study medication, with NRI for patients with treatment failure or missing data, including those who did not enter the LTE ^dLTE efficacy analysis set consists of randomized patients who entered the LTE and received ≥1 dose of study medication in the LTE, with NRI for patients with treatment failure or missing data ^eObserved case analysis set consists of randomized patients who entered the LTE, received ≥1 dose of study medication in the LTE, and had available data at the outcome visit. Patients who received dose adjustment were excluded

Conclusion

Durable clinical and endoscopic efficacy was maintained over time through Week 144 of the LTE. The safety profile of GUS was consistent with that of the approved indications. Most infections were not serious and did not result in discontinuation, while incidence rates of SAEs and serious infections were generally low.

Disclosure

Anita Afzali, M.D. is a consultant, speaker, clinical investigator, and advisory board member for Janssen
Silvio Danese, M.D. is a consultant and speaker for Janssen
Remo Panaccione, M.D. is a consultant, clinical investigator, and speaker for Janssen
Brian G. Feagan, M.D. is a consultant, speaker, member of a data safety monitoring board, and advisory board member for Janssen
David T. Rubin, M.D. is a consultant for Janssen
Bruce E. Sands, M.D. is a consultant and speaker for Janssen
Walter Reinisch, M.D. is a clinical investigator, speaker, and advisory board member for Janssen
Julián Panés, M.D. is a consultant, speaker, clinical investigator, advisor, and member of a data safety monitoring board for Janssen
Aparna Sahoo, D.O. is an employee of Janssen
Natalie A. Terry, M.D. is an employee of Janssen
Leonardo Salese, M.D. is an employee of Janssen
Chris Corbett, M.Sc. is an employee of Janssen
Tadakazu Hisamatsu, M.D. is a clinical investigator for Janssen
Jane M. Andrews, M.D. is a clinical investigator and consultant for Janssen
Geert R D’Haens, M.D. is a consultant for Janssen

EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION

Anita Afzali 1, Silvio Danese 2, Remo Panaccione 3, Brian G. Feagan 4, David T. Rubin 5, Bruce E. Sands 6, Walter Reinisch 7, Julian Panés 8, Aparna Sahoo 9, Natalie Terry 9, Leonardo Salese 9, Christopher Corbett 10, Tadakazu Hisamatsu 11, Jane Andrews 12, Geert R. D'Haens 13

1 University of Cincinnati, Cincinnati, United States

2 Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Netherlands

3 University of Calgary, Calgary, Canada

4 The University of Western Ontario, London, Canada

5 University of Chicago Medicine, Chicago, United States

6 Icahn School of Medicine at Mount Sinai, New York, United States

7 Medical University of Vienna, Wien, Austria

8 Hospital Clínic Barcelona, Barcelona, Spain

9 Janssen, Spring House, United States

10 Janssen UK, Wycombe, United Kingdom

11 Kyorin University, Tokyo, Japan

12 Royal Adelaide Hospital, Adelaide, Australia

13 AMC Amsterdam Inflammatory Bowel Disease Centre - Academic Medical Center, AMC Amsterdam Inflammator, Amsterdam, Netherlands

Event

UEG Week Copenhagen 2023

Topics

Endoscopy IBD

Submission format

Abstract

Session

IL-23-Blockers in IBD: Part 1

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

UEG Poster

Audio / Video Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Eosinophilic esophagitis (EoE) is a chronic type 2 inflammatory disease with increasing incidence and prevalence. Patients with EoE usually present with symptoms of dysphagia that impact their quality of life. In the 3-part, Phase 3 LIBERTY EoE TREET study (NCT03633617), dupilumab improved histologic, symptomatic, and endoscopic aspects of EoE up to 52 weeks.

Aims & Methods

The aim of this analysis was to assess the effect of dupilumab on symptoms of dysphagia in the 28-week extended treatment period of LIBERTY EoE TREET in patients who switched from placebo to dupilumab at 24 weeks. In Parts A and B, patients received dupilumab 300 mg or placebo weekly (qw) for 24 weeks. Patients who completed Parts A and B entered Part C - a 28-week extended treatment period in which all patients received dupilumab 300 mg qw; patients entering Part C remained blinded to their treatment in Parts A and B. Dysphagia Symptom Questionnaire (DSQ) score and number of days with dysphagia (assessed using the DSQ) were calculated over a 14-day period. Percent change in DSQ score and in number of days with dysphagia from Week 24 through Week 52 vs the Week 24 baseline were assessed for patients who switched from placebo to dupilumab 300 mg qw at Week 24 and or continued on dupilumab 300 mg.

Results

Mean (SD) DSQ score after 24 weeks of placebo was 24.7 (19.6) and 21.5 (18.4) in Parts A (n=37) and B (n=37), respectively. Significant improvements in DSQ score were observed within 4 weeks of the switch to dupilumab 300 mg qw (mean percent reduction: 31.5% and 29.9%). After 28 weeks (at Week 52), mean percent reduction in DSQ score was 63.6% and 59.7%. After 24 weeks of placebo, mean (SD) days with dysphagia was 6.6 (4.7) and 6.0 (4.7) in Parts A and B, respectively. At Week 52, there was a 63.2% and 46.8% mean reduction in the number of days with dysphagia.

Conclusion

In patients who initially received 24 weeks of placebo, weekly treatment with dupilumab 300 mg resulted in rapid (within 4 weeks) and sustained (up to 28 weeks) improvement in symptoms of dysphagia as assessed by the DSQ score. The magnitude of the improvement in dysphagia observed after switching from placebo to dupilumab was similar to that seen at 4 weeks in patients who originally initiated dupilumab in Parts A and B of the study.

Disclosure

Dellon ES. Abbott, Abbvie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Dr. Falk Pharma, Eli Lilly, EsoCap, Eupraxia, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, Upstream Bio – consultant. Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Shire/Takeda – research funding. Allakos, Aqilion, Holoclara, Invea – educational grants.
Chehade M. Adare Pharma Solutions/Ellodi, Allakos, AstraZeneca, BMS, Nexstone Immunology, Phathom, Recludix Pharma, Regeneron Pharmaceuticals Inc., Sanofi, and Shire/Takeda ‒ consultant. Adare Pharma Solutions/Ellodi, Allakos, AstraZeneca, Celgene/BMS, Danone, Regeneron Pharmaceuticals Inc., and Shire/Takeda ‒ research funding.
Bredenoord AJ. Alimentiv, Aqilion, AstraZeneca, Dr. Falk Pharma, Eupraxia, Laborie, Medtronic, Reckitt, Regeneron Pharmaceuticals Inc., and Sanofi ‒ consultant. Dr Falk Pharma, Norgine, Nutricia, Sanofi, SST, Regeneron Pharmaceuticals Inc., and Thelial ‒ research funding. Alimentiv, Aqilion, AstraZeneca, Dr Falk Pharma, Eupraxia, Laborie, Medtronic, Reckitt, Regeneron Pharmaceuticals Inc., and Sanofi ‒ speaker fees.
Spergel JM. Allakos, DBV Technologies, Novartis, Regeneron Pharmaceuticals Inc., and Shire/Takeda – consultant. DBV Technologies and Regeneron Pharmaceuticals Inc. ‒ research grant support.
Xia C, McCann E, Khodzhayev A, Radwan A. Regeneron Pharmaceuticals Inc. – employees and shareholders.
Tilton ST, Pela T, Jacob-Nara JA. Sanofi – employee, may hold stock and/or stock options in the company.

DUPILUMAB LED TO RAPID AND SUSTAINED IMPROVEMENT IN DYSPHAGIA IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS AFTER SWITCHING FROM PLACEBO: RESULTS FROM PART C OF THE LIBERTY EOE TREET STUDY

Evan S. Dellon 1, Mirna Chehade 2, Albert J. Bredenoord 3, Jonathan M. Spergel 4, Changming Xia 5, Sarette Tilton 6, Eilish McCann 5, Tiffany Pela 6, angela khodzhayev 5, Juby Jacob-Nara 6, Amr Radwan 5

1 University of North Carolina School of Medicine, Chapel Hill, United States

2 Mount Sinai Center For Eosinophilic Disorders, Icahn School Of Medicin, New York, United States

3 Amsterdam University Medical Center, Amsterdam, Netherlands

4 Perelman School of Medicine at University of Pennsylvania School of Medicine, Philadelphia, United States

5 Regeneron Pharmaceuticals Inc., Tarrytown, United States

6 Sanofi, Bridgewater, United States

Conference

UEG Week Vienna 2024

Topics

Oesophagus

Submission format

Abstract

Session

Pharmaceutical treatment of EoE (Posters)

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Most popular content

Rate for better recommendations!